Targeted therapy for HM1.24 (CD317) on multiple myeloma cells

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Multiple myeloma (MM) is an incurable blood cancer.
• Drug-resistant MM cells and cancer stem cells (CSCs) contribute to treatment failure.
• Immunological approaches, including monoclonal antibodies (mAbs) and cytotoxic T lymphocytes (CTLs), show promise for MM treatment.

Purpose of the Study:

• To investigate HM1.24 (BST2/CD317) as a therapeutic target in MM.
• To develop novel immunotherapeutic strategies against MM, including targeting MM CSCs.
• To evaluate the potential of combining HM1.24-targeted mAbs and CTLs for MM treatment.

Main Methods:

• Identified HM1.24 overexpression on mature MM cells and MM CSCs.
• Developed a humanized mAb against HM1.24, including a defucosylated version for clinical use.
• Generated HM1.24-specific CTLs for potential anti-MM immunotherapy.

Main Results:

• HM1.24 is confirmed to be overexpressed on both mature MM cells and MM CSCs.
• Successfully developed a humanized anti-HM1.24 mAb and induced HM1.24-specific CTLs.
• The developed immunotherapeutic agents show potential for clinical application against MM.

Conclusions:

• HM1.24 is a promising therapeutic target for multiple myeloma.
• Combination immunotherapy targeting HM1.24 may overcome drug resistance and eliminate MM CSCs.
• This novel approach offers a potential strategy to improve outcomes for patients with multiple myeloma.